developed a prognostic model in a multicenter study that synergistically integrates digital histopathological imaging with multimodal clinical data to predict recurrence risk in hormone receptor‐positive/human epidermal growth factor receptor 2‐negative (HR+/HER2‐) early‐stage breast cancer patients receiving adjuvant chemo‐endocrine therapy. This evidence concerns the gene ERBB2 and breast carcinoma.